scholarly article | Q13442814 |
P50 | author | Alberto M Martelli | Q56922777 |
Jörg Baesecke | Q69033710 | ||
Ferdinando Nicoletti | Q84521195 | ||
Linda S Steelman | Q114723345 | ||
Franca Stivala | Q114723350 | ||
Stephen L Abrams | Q123366731 | ||
William H Chappell | Q123366743 | ||
Massimo Libra | Q37842996 | ||
Marco Donia | Q40146733 | ||
James A. McCubrey | Q42317570 | ||
P2093 | author name string | John G Shelton | |
P2860 | cites work | Pseudo-DNA damage response in senescent cells | Q28583844 |
ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate | Q33415974 | ||
New agents for the treatment of acute myeloid leukemia | Q36413300 | ||
Program-like aging and mitochondria: instead of random damage by free radicals | Q36988252 | ||
Targeting prostate cancer based on signal transduction and cell cycle pathways. | Q36995054 | ||
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects | Q37032524 | ||
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. | Q37109225 | ||
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | Q46441674 | ||
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism | Q46666883 | ||
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells | Q46956224 | ||
Genomic instability en route to and from cancer stem cells. | Q53312262 | ||
Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. | Q53440045 | ||
Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. | Q53446661 | ||
MNK, EIF4E and targeting translation for therapy. | Q53499743 | ||
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion | Q56995355 | ||
Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms | Q69738450 | ||
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes | Q80599609 | ||
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 | ||
Cancer stem cell and cancer stemloids: from biology to therapy | Q37111467 | ||
The tumor suppressor p53: cancer and aging | Q37138969 | ||
Cancer stem cells and survival pathways | Q37141755 | ||
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches | Q37192606 | ||
Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells | Q37253119 | ||
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy | Q37272565 | ||
Aging: ROS or TOR. | Q37312907 | ||
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. | Q37331720 | ||
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 | ||
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors | Q37355543 | ||
Targeting mTOR with rapamycin: one dose does not fit all | Q37409171 | ||
Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors | Q37554117 | ||
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. | Q39783675 | ||
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence | Q39845659 | ||
Rapamycin decelerates cellular senescence | Q39846812 | ||
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. | Q39869731 | ||
Growth stimulation leads to cellular senescence when the cell cycle is blocked | Q39925937 | ||
Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. | Q39943580 | ||
GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma | Q39943592 | ||
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. | Q39991616 | ||
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia | Q39991646 | ||
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy | Q40077070 | ||
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts | Q40184405 | ||
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. | Q40287051 | ||
P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. | Q40790669 | ||
Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and posttranscriptional mechanisms | Q41207196 | ||
Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cells | Q41282247 | ||
The CML stem cell: evolution of the progenitor | Q42135962 | ||
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 | ||
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 | ||
At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. | Q45995695 | ||
Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. | Q46008332 | ||
Translational control and cancer therapy | Q46372387 | ||
Cancer and aging: more puzzles, more promises? | Q46417167 | ||
P433 | issue | 8 | |
P921 | main subject | chemotherapy | Q974135 |
apoptotic process | Q14599311 | ||
P1104 | number of pages | 10 | |
P304 | page(s) | 1629-1638 | |
P577 | publication date | 2010-04-15 | |
P1433 | published in | Cell Cycle | Q1254166 |
P1476 | title | Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs | |
P478 | volume | 9 |
Q27686983 | Advances in targeting signal transduction pathways |
Q36351612 | Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. |
Q92645527 | Clinicopathological significance of ribosomal protein S6 kinase A6 in lung squamous cell carcinoma: an immunohistochemical and RNA-seq study |
Q35640301 | Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells |
Q36189476 | Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization |
Q92208308 | Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway |
Q36556350 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine |
Q39182610 | Effect of Chaihushugan San on expression of the Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase pathway in the hippocampi of perimenopausal rats induced by immobilization stress |
Q37192616 | Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy |
Q35556981 | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells |
Q39116774 | Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling. |
Q36304116 | MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2. |
Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
Q36477469 | Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. |
Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
Q39441370 | Selective Targeting of RSK Isoforms in Cancer |
Q31114420 | Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data |
Q36179524 | Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. |
Q47110143 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells |
Q37618829 | The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system |
Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |